

## Supplementary Data

### **Binding of a potential anti-hepatoma compound**

***cis,cis,trans*-[Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>(O<sub>2</sub>CCH<sub>2</sub>CH<sub>2</sub>COOH)-**

**(OCONHC<sub>16</sub>H<sub>33</sub>)] with serum albumin ---**

### **thermodynamic and conformational investigations**

Li Qi, Zhong Lu<sup>1</sup>, Wen-hua Lang, Lu Guo, Chang-geng Ma, Guang-hong Sun

Clinical College of Weifang Medical University, Weifang 261031, China

---

<sup>1</sup>Corresponding author. Tel: +86-05368068895, Fax: +86-05368068895.  
E-mail address: [luzhongdoc1103@hotmail.com](mailto:luzhongdoc1103@hotmail.com) (Zhong Lu)




Fig. S1. NMR and ESI-MS spectra of the Pt<sup>4+</sup> compound: (a) <sup>1</sup>H NMR spectrum of the Pt<sup>4+</sup> compound in DMSO-d<sub>6</sub>; (b) <sup>13</sup>C NMR spectrum of the Pt<sup>4+</sup> compound in DMSO-d<sub>6</sub>; (c) <sup>195</sup>Pt NMR spectrum of the Pt<sup>4+</sup> compound in DMSO-d<sub>6</sub>; (d) ESI-MS of the Pt<sup>4+</sup> compound.




Fig. S2. HPLC trace of the Pt<sup>4+</sup> compound.




Fig. S3. Fluorescence intensity changes of HSA ( $1.0 \times 10^{-6}$  M) in the presence of the  $\text{Pt}^{4+}$  compound ( $1.0 \times 10^{-5}$  M) with various NaCl concentrations